

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

**RESIGNATION OF NON-EXECUTIVE DIRECTOR;
RESIGNATION AND PROPOSED APPOINTMENT OF
INDEPENDENT NON-EXECUTIVE DIRECTOR AND
MEMBER OF THE STRATEGIC COMMITTEE**

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Reference is also made to the overseas regulatory announcements dated 9 December 2022.

(1) Resignation of directors of the Company

Resignation of non-executive director of the Company

Mr. Lin Lijun (“**Mr. Lin**”) has tendered his resignation as non-executive director of the Company with effect from 8 December 2022 due to other work arrangements.

Mr. Lin has confirmed that he has no disagreement with the board (the “**Board**”) of director of the Company (the “**Directors**”), and there are no other matters that should be brought to the attention of the shareholders of the Company (the “**Shareholders**”) in relation to his resignation.

Resignation of independent non-executive Director and member of the Strategic Committee of the Company

Dr. Chen Lieping (“**Dr. Chen**”) has tendered his resignation as independent non-executive director of the Company and member of the Strategic Committee of the Company due to other work arrangements. Dr. Chen will continue to carry out his duties until, and his resignation will become effective upon, the appointment of a new independent non-executive Director. Dr. Chen has confirmed that he has no disagreement with the Board, and there are no other matters that should be brought to the attention of the Shareholders in relation to his resignation.

The Board would like to take this opportunity to express its sincere gratitude to each of Mr. Lin and Dr. Chen for his contributions to the Company during his tenure of office.

(2) Proposed appointment of independent non-executive Director and member of the Strategic Committee of the Company

The Board has considered and approved to nominate Dr. Meng Anming (“**Dr. Meng**”) as a candidate for independent non-executive Director. The appointment of Dr. Meng as independent non-executive Director will be proposed for consideration and approval by the Shareholders at the general meeting of the Company.

The biography of Dr. Meng is as follows:

Dr. Meng Anming (孟安明), aged 59, received a bachelor’s degree in agronomy from Southwest Agricultural University* (西南農業大學) in July 1983, and a doctorate degree in genetics from the University of Nottingham in November 1990. He was elected as an academician of the Chinese Academy of Sciences in 2007 and an academician of The World Academy of Sciences for the advancement of science in developing countries in 2008. From December 1990 to December 1992, he worked as a postdoctoral researcher at the School of Biology, China Agricultural University. From December 1992 to August 1998, he served as an associate professor at the School of Biology, China Agricultural University, during which from March 1996 to August 1998, he was a visiting scholar at the Institute of Molecular Medicine and Genetics, Medical College of Georgia in the United States. Since August 1998, he has been a professor at the School of Life Sciences, Tsinghua University.

As at the date of this announcement, save as disclosed above, Dr. Meng has confirmed that he: (i) does not hold any position in the Company or any other subsidiaries of the Company, nor did he hold any directorship or positions of supervisor in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iii) does not have any interests in the shares or underlying shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). If Dr. Meng is appointed as an independent non-executive Director at the general meeting of the Company, the Company will enter into a service contract with Dr. Meng in relation to his appointment as independent non-executive Director for a term commencing from the date of approval of his appointment at the general meeting of the Company and expiring on the conclusion of the third session of the Board, which is subject to retirement by rotation and re-appointment in accordance with the articles of association of the Company and the Listing Rules. The remuneration of Dr. Meng will be determined with reference to his duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee of the Company from time to time. Dr. Meng has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Listing Rules requiring the prior approval of Shareholders at general meetings, with the Company. Save as disclosed above, there are no other matters concerning Dr. Meng’s appointment as independent non-executive Director that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The appointment of Dr. Meng as independent non-executive Director is subject to the approval of the Shareholders by way of ordinary resolution at the general meeting of the Company. Notice of the general meeting and a circular containing, among other things, details of the above proposal will be despatched to the Shareholders in due course.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 9 December 2022

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive Directors; Dr. Wu Hai and Mr. Tang Yi as non-executive Directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive Directors.

* *For identification purpose only*